SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION vs Viz RV/LV

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by DIACOUSTIC MEDICAL DEVICES (PTY)
VS
by Viz.ai

AI Verdict

Tool A assists physicians in diagnosing heart murmurs by analyzing acoustic heart signals, primarily for general cardiology and pediatrics. Tool B, conversely, automates ventricular measurements from CTPA scans to stratify pulmonary embolism risk, serving emergency medicine, pulmonology, and radiology. While both are FDA-cleared cardiology AI tools, their distinct input data (acoustic vs. imaging) and clinical applications make them suitable for different diagnostic pathways.

Choose SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION if…

Choose SensiCardiac Mobi if your clinical practice requires an AI-powered mobile solution for real-time, point-of-care heart murmur assessment using an electronic stethoscope. This tool is ideal for physicians in internal medicine, pediatrics, or cardiology who need to quickly differentiate between physiological and pathological heart sounds to guide further diagnostic steps or specialist referrals.

View SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION →

Choose Viz RV/LV if…

Choose Viz RV/LV if your institution needs an automated, AI-driven solution for rapid risk stratification of pulmonary embolism patients based on CTPA scans. This tool is best suited for emergency medicine, radiology, and pulmonology departments that require immediate RV/LV ratio measurements and seamless care team coordination to optimize treatment pathways for suspected PE.

View Viz RV/LV →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION Viz RV/LV
Pricing Contact for pricing Not publicly available
Deployment Hosted server environment (Linux OS) with a mobile application interface Cloud-based
BAA Available Yes AI-estimated Yes AI-estimated
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Viz RV/LV

Tool B (Viz RV/LV) offers a more comprehensive and integrated user experience within an enterprise healthcare setting, featuring a mobile DICOM image viewer, HIPAA-compliant communication platform, and seamless integration with existing PACS and EHR systems. While Tool A (SENSICARDIAC MOBI) provides a mobile application with good usability for its specific function, Tool B's broader capabilities for care coordination across a network make it more versatile in complex clinical workflows.

Clinical Value

Viz RV/LV

Both tools offer significant clinical value, but Tool B (Viz RV/LV) provides rapid, automated risk stratification for acute pulmonary embolism (PE), a life-threatening condition. Its automated RV/LV ratio measurement from CTPA scans directly impacts timely intervention and care coordination, which is critical in high-stakes emergency scenarios. Tool A (SENSICARDIAC MOBI) aids in the diagnosis of heart murmurs, which is important, but typically less time-critical than PE risk stratification.

Pricing & Value

Tie

Neither Tool A nor Tool B publicly discloses their pricing information. Without any transparent pricing details or comparative data on their cost-effectiveness, it is impossible to determine which tool offers better pricing or overall value to healthcare organizations.

Enterprise Readiness

Viz RV/LV

Tool B (Viz RV/LV) demonstrates superior enterprise readiness with its cloud-based architecture, extensive security and compliance certifications (including SOC 2 Type II and multiple ISOs), and proven seamless integration with PACS and EHR systems as part of the Viz.ai One platform. Its partnership with Microsoft Cloud for Healthcare further solidifies its robust, scalable, and secure infrastructure for large healthcare organizations. Tool A, while HIPAA compliant and FDA cleared, appears to be a more standalone mobile application with a hosted server, lacking the explicit enterprise-level integration and comprehensive security framework highlighted by Tool B.

Innovation

Viz RV/LV

Both tools are innovative, but Tool B (Viz RV/LV) represents a more comprehensive innovation by automating a critical and time-sensitive measurement from imaging data and integrating it into an intelligent care coordination platform for a life-threatening condition. Viz.ai is recognized as a pioneer in using AI for acute and emergent diseases, offering a broader platform approach to streamlining urgent care pathways. Tool A's AI-powered acoustic analysis for heart murmurs is innovative for its specific application, but less expansive in its impact on system-wide care coordination.

Support & Docs

Viz RV/LV

Tool B (Viz RV/LV) offers a significantly more robust support and documentation ecosystem, including a dedicated Help Center, Customer Resources, User Guides, Viz Academy, and 24/7 urgent phone support. This comprehensive support structure is essential for complex enterprise-level AI solutions. Information regarding support for Tool A is limited to general user manuals, suggesting a less extensive and readily accessible support infrastructure.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION Viz RV/LV
Tool Name SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION Viz RV/LV
Company DIACOUSTIC MEDICAL DEVICES (PTY) Viz.ai
Description SensiCardiac Mobi is an FDA-cleared AI-powered mobile application that assists physicians in diagnosing heart murmurs by analyzing acoustic heart signals from an electronic stethoscope to differentiate between physiological and pathological sounds. Viz RV/LV by Viz.ai is an FDA-cleared AI algorithm that automates right and left ventricular diameter measurements from CTPA scans, providing a crucial RV/LV ratio for rapid pulmonary embolism risk stratification and enhanced care coordination within the Viz PE Solution.
Primary Function Diagnosing heart murmurs by analyzing acoustic heart signals Automates right and left ventricular diameter measurements from CTPA scans for pulmonary embolism risk stratification
Input Data Acoustic heart signals from an electronic stethoscope Volumetric CTPA acquisitions
Key Output Distinguishes between normal/physiological and pathological heart murmurs; Identifies S1, S2, and suspected murmurs Automated Right Ventricle (RV) to Left Ventricle (LV) ratio measurement; Annotated images showing ventricular measurements
Specialties Cardiology, Internal Medicine, Pediatrics Emergency Medicine, Pulmonology, Radiology

Videos

Demos, reviews, and walkthroughs featuring SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION and Viz RV/LV.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

SensiCardiac Mobi assists physicians by acquiring and analyzing acoustic heart signals from an electronic stethoscope, complementing the physician's assessment to differentiate heart murmurs during a physical exam. Viz RV/LV automates RV/LV ratio measurements from CTPA scans for rapid pulmonary embolism risk stratification and enhances care coordination within the Viz PE Solution, integrating into an acute care workflow for suspected pulmonary embolism detection.
SensiCardiac Mobi's description focuses on its mobile application for data capture and display, and does not explicitly detail EHR integration capabilities for automated documentation of heart sound analysis results. Viz RV/LV is a seamless component of the Viz PE Solution, providing AI-powered alerts and notifications to care teams and a HIPAA-compliant communication platform for care coordination, suggesting integration for streamlined communication and data flow within the broader PE solution.
SensiCardiac Mobi uses the Sensi Diagnostic Heart Murmur Algorithm to analyze heart sounds and distinguish between normal/physiological and pathological heart murmurs, but specific accuracy or sensitivity metrics for this differentiation are not provided in the given facts. Viz RV/LV employs an AI algorithm for the identification and measurement of heart ventricles to provide a crucial RV/LV ratio from CTPA scans, however, the provided information does not detail specific performance metrics like accuracy or sensitivity for this automated measurement.
For SensiCardiac Mobi, physicians would need to learn to effectively acquire and record acoustic heart signals at four main auscultation positions using a compatible electronic stethoscope with the mobile application. With Viz RV/LV, the AI algorithm automates measurements and provides annotated images, so the learning curve would likely involve understanding how to interpret these AI-generated measurements and integrate the AI-powered alerts into clinical decision-making for pulmonary embolism risk stratification.
The provided information for SensiCardiac Mobi does not detail the specific level of ongoing technical or clinical support available, nor does it mention the availability of customer references. Similarly, the description for Viz RV/LV does not specify the nature of ongoing support or indicate whether customer references are available to demonstrate real-world implementation success.
For SensiCardiac Mobi, multi-site rollout considerations would include managing the provision of compatible electronic stethoscopes and deploying the mobile application across various clinical settings, with time-to-value linked to integrating this diagnostic support into diverse cardiology, internal medicine, and pediatric workflows. For Viz RV/LV, a multi-site implementation would involve integrating the cloud-based AI algorithm with existing CTPA imaging infrastructure across different sites and leveraging its communication platform for enhanced care coordination, aiming to achieve rapid time-to-value through expedited pulmonary embolism risk stratification.

Backers

Who funded each tool's parent company.

AI Tool Finder
AI-powered search. Results may not be comprehensive.